ANGPTL3 and coronary artery disorder: In our positive control analysis for CHD, we observed significant associations between genetic proxy drug targets and reduced risk of CHD for all genes except ANGPTL3 (Fig. 3), demonstrating the effectiveness of the selected genetic instruments.